Ozkara Burak B, Federau Christian, Dagher Samir A, Pattnaik Debajani, Ucisik F Eymen, Chen Melissa M, Wintermark Max
Department of Neuroradiology, MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.
Faculty of Medicine, University of Zurich, Pestalozzistrasse 3, Zurich, CH-8032, Switzerland.
J Neurooncol. 2023 Apr;162(2):363-371. doi: 10.1007/s11060-023-04297-4. Epub 2023 Mar 29.
The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group proposed a guide for treatment responses for BMs by utilizing the longest diameter; however, despite recognizing that many patients with BMs have sub-centimeter lesions, the group referred to these lesions as unmeasurable due to issues with repeatability and interpretation. In light of RANO-BM recommendations, we aimed to correlate linear and volumetric measurements in sub-centimeter BMs on contrast-enhanced MRI using intelligent automation software.
In this retrospective study, patients with BMs scanned with MRI between January 1, 2018, and December 31, 2021, were screened. Inclusion criteria were: (1) at least one sub-centimeter BM with an integer millimeter-longest diameter was noted in the MRI report; (2) patients were a minimum of 18 years of age; (3) patients with available pre-treatment three-dimensional T1-weighted spoiled gradient-echo MRI scan. The screening was terminated when there were 20 lesions in each group. Lesion volumes were measured with the help of intelligent automation software Jazz (AI Medical, Zollikon, Switzerland) by two readers. The Kruskal-Wallis test was used to compare volumetric differences.
Our study included 180 patients. The agreement for volumetric measurements was excellent between the two readers. The volumes of the following groups were not significantly different: 1-2 mm, 1-3 mm, 1-4 mm, 2-3 mm, 2-4 mm, 3-4 mm, 3-5 mm, 4-5 mm, 5-6 mm, 5-7 mm, 6-7 mm, 6-8 mm, 6-9 mm, 7-8 mm, 7-9 mm, 8-9 mm.
Our findings indicate that the largest diameter of a lesion may not accurately represent its volume. Additional research is required to determine which method is superior for measuring radiologic response to therapy and which parameter correlates best with clinical improvement or deterioration.
神经肿瘤脑转移瘤疗效评估(RANO-BM)工作组提出了一项利用最长径来评估脑转移瘤治疗反应的指南;然而,尽管认识到许多脑转移瘤患者存在亚厘米级病变,但由于重复性和解读问题,该小组将这些病变视为不可测量。根据RANO-BM的建议,我们旨在使用智能自动化软件,对对比增强MRI上亚厘米级脑转移瘤的线性和体积测量结果进行相关性分析。
在这项回顾性研究中,我们筛选了2018年1月1日至2021年12月31日期间接受MRI扫描的脑转移瘤患者。纳入标准为:(1)MRI报告中记录至少有一个最长径为整数毫米的亚厘米级脑转移瘤;(2)患者年龄至少18岁;(3)有治疗前三维T1加权扰相梯度回波MRI扫描资料。每组有20个病变时筛选终止。由两名阅片者借助智能自动化软件Jazz(AI Medical,瑞士苏黎世)测量病变体积。采用。采用Kruskal-Wallis检验比较体积差异。
我们的研究纳入了180例患者。两名阅片者之间体积测量的一致性极佳。以下几组的体积无显著差异:1 - 2毫米、1 - 3毫米、1 - 4毫米、2 - 3毫米、2 - 4毫米、3 - 4毫米、3 - 5毫米、4 - 5毫米、5 - 6毫米、5 - 7毫米、6 - 7毫米、6 - 8毫米、6 - 9毫米、7 - 8毫米、7 - 9毫米、8 - 9毫米。
我们的研究结果表明,病变的最大径可能无法准确代表其体积。需要进一步研究以确定哪种方法在测量治疗的放射学反应方面更优,以及哪个参数与临床改善或恶化的相关性最佳。